Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business highlights.

BOULDER, Colo., March 03, 2025--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full ...

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights May 08, 2025 8:00 AM ET Edgewise Therapeutics, Inc. (EWTX) Q1: 2025-05-08 Earnings Summary ...

The Company plans to engage the U.S. FDA in the first half of 2025 to discuss marketing ... compared to $34.1 million or $0.36 per share for the immediately preceding quarter. About Edgewise ...

Edgewise Therapeutics, Inc.,, a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. "We continue to ...

Net loss and net loss per share for the first quarter of 2025 was $40.8 million or $0.43 per share, compared to $39.7 million or $0.42 per share for the preceding quarter. About Edgewise Therapeutics ...

– Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – – On track to report data from ...

– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – ...